Cardiovascular Effects of Vyvanse in ADHD Patients

Introduction to Cardiovascular Risks

Stimulant medications, including Vyvanse, increase heart rate by an average of 1-2 beats per minute and blood pressure by 1-4 mmHg, according to the American Academy of Pediatrics 1
A subset of individuals (5-15%) may experience more substantial increases in heart rate and blood pressure, as reported by the American Academy of Pediatrics 1

Personal history of cardiac symptoms is a risk factor for experiencing cardiovascular side effects with Vyvanse, as noted by the American Academy of Pediatrics 1
Family history of sudden death, cardiovascular symptoms, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, or long QT syndrome is a risk factor for experiencing cardiovascular side effects with Vyvanse, according to the American Academy of Pediatrics 1
Pre-existing hypertension or tachyarrhythmias are risk factors for experiencing cardiovascular side effects with Vyvanse, as reported by the National Comprehensive Cancer Network 2, 3

The American Academy of Pediatrics recommends monitoring heart rate and blood pressure regularly during treatment with Vyvanse 1
The National Comprehensive Cancer Network suggests considering dose reduction if palpitations or other cardiovascular symptoms occur 3
The National Comprehensive Cancer Network recommends scheduling medication earlier in the day to minimize sleep disturbance that can exacerbate palpitation awareness 3
For patients with significant cardiovascular risk factors, the American Academy of Pediatrics recommends considering obtaining an ECG before starting treatment with Vyvanse 1
In cases of severe or persistent palpitations, the American Academy of Pediatrics suggests considering switching to a non-stimulant medication for ADHD, such as atomoxetine, guanfacine, or clonidine 1

The overall risk of serious cardiovascular events with stimulant medications is extremely low, as reported by the American Academy of Pediatrics 1
The American Academy of Pediatrics notes that studies have not shown an increased risk of sudden cardiac death in patients taking stimulants compared to those not receiving stimulants 1